<DOC>
	<DOCNO>NCT00426751</DOCNO>
	<brief_summary>Multinational , multicentre , randomise , prospective , open , parallel group study directly compare two glycoprotein-IIb/IIIa inhibitor , abciximab eptifibatide , add early standard treatment primary PCI STEMI patient respect effect sum-ST-resolution 60 minute post-procedure measure myocardial reperfusion</brief_summary>
	<brief_title>Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention ( PCI ) For Acute ST Elevation Myocardial Infarction ( STEMI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Women must postmenopausal ( i.e.12 month without menstrual period ) , surgically sterile , i.e . woman child bear potential allow include study . In case doubt pregnancy test perform . ( NB post menopausal woman currently receive hormone replacement permissible ) Acute myocardial infarction &lt; 12 h define : 1 . Angina equivalent symptom &gt; 20 min 2 . ST elevation 2 contiguous ECG lead ( = 2 mm precordial lead , = 1 mm limb lead ) . This ECG record serf baseline ECG , i.e . ECG I . Planned primary percutaneous coronary intervention The subject give write inform , dated consent participate study Subjects able give inform consent Left Bundle Branch Block Thrombolytic therapy within 24 hour randomization Oral anticoagulation International Normalized Ratio ( INR ) &gt; 2 Known platelet &lt; 100.000/Âµl know hemorrhagic diathesis Stroke Transient Ischemic Attack ( TIA ) within past 6 month permanent residual neurological defect Evidence active gastrointestinal urogenital bleeding Major surgery within 6 week History allergic reaction abciximab eptifibatide component use study ( include contrast medium ) Known severe renal ( creatinine clearance &lt; 30ml/min ) hepatic insufficiency well Alanine transaminase ( ALT ) /aspartate transaminase ( AST ) elevation = 3xUpper limit normal ( ULN ) ; isolate ASTelevation consider exclusion criterion study participation Severe concomitant disease life expectation &lt; 1 year Subject participate study use investigational drug device within 30 day within 5 halflives investigational drug ( whichever longer ) entry study . Subjects inaccessible due geographic social factor treatment followup In France , subject neither affiliated beneficiary social security category .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Eptifibatide</keyword>
	<keyword>ST-elevation Myocardial Infarction</keyword>
	<keyword>STEMI</keyword>
	<keyword>Abciximab</keyword>
</DOC>